Testing a blood protein for heart and blood vessel problems in scleroderma
Part of Skin clinical trials.
This study is looking at whether a protein in your blood called catestatin can help doctors see how scleroderma is affecting your heart and small blood vessels. If you have scleroderma, joining could help doctors better monitor the disease and its effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of systemic sclerosis (also called scleroderma) using the 2013 ACR-EULAR criteria.
- You must be at least 18 years old.
- You must not have any other autoimmune diseases (like lupus or rheumatoid arthritis).
- You must not have heart conditions unrelated to scleroderma.
- You must not have diabetes, chronic kidney disease, or obesity, as these could affect the test results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at tiny particles in your blood to see if they can predict whether you might develop a serious lung condition called pulmonary arterial hypertension (high blood pressure in the lungs). It aims to find better ways to detect and manage this complication early.
This study follows adults with systemic scleroderma (also called scleroderma) to better understand the condition over time. You may be included if you meet specific diagnosis and blood-test requirements and can give informed consent.
This study looks at skin cells and immune cells in people with systemic sclerosis to better understand what drives the disease. Your participation may help researchers learn how the immune system and skin support cells change over time.
This study looks at a specific type of immune cell activity (called neutrophil extracellular traps) in the blood of people with systemic sclerosis, other connective tissue diseases, and healthy volunteers. It aims to understand how these cells may be involved in the disease and could lead to better treatments.
This study looks for blood and tissue “biomarkers” (measurable clues in samples) to help diagnose and predict outcomes in inflammatory muscle diseases and systemic sclerosis (a skin/organ condition). If you’re being evaluated for myopathy or early scleroderma, it may help doctors sort out the cause and follow your health more closely.
This study looks at using chest CT scans to help predict how lung disease from scleroderma (SSc-ILD) may progress. It may help doctors better understand your condition.
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.